Clinical impact of stent construction and design in percutaneous coronary intervention

American Heart Journal

Volumn 147, Issue 5, 2004, Pages 764-773

  Lau, Kean Wah ^a   Mak, Koon Hou ^a   Hung, Jui Sung ^a   Sigwart, Ulrich ^a  

^a DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GOLD; HEPARIN; PACLITAXEL; PHOSPHORYLCHOLINE; RAPAMYCIN; SILICON CARBIDE;

ARTERY INTIMA PROLIFERATION; BLOOD VESSEL INJURY; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CORONARY ARTERY ANEURYSM; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY PERFORATION; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG SAFETY; HUMAN; IN STENT RESTENOSIS; INFLAMMATION; MATERIAL COATING; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; RISK ASSESSMENT; WOUND HEALING IMPAIRMENT;

EID: 3042851780     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.12.007     Document Type: Article

References (92)

1. Sigwart U., Puel J., Mirkovitch V., et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 316:1987;701-706
2. Serruys P.W., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 331:1994;489-495
3. Fischman D.L., Leon M.B., Baim D.S., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 331:1994;496-501
4. Barth K.H., Virmani R., Froelich J., et al. Paired comparison of vascular wall reactions to Palmaz stents, Strecker tantalum stents, and Wallstents in canine iliac and femoral arteries. Circulation. 93:1996;2161-2169
5. Rogers C., Edelman E.R. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation. 91:1995;2995-3001
6. Garasic J.M., Edelman E.R., Squire J.C., et al. Stent and artery geometry determine intimal thickening independent of arterial injury. Circulation. 101:2000;812-818
7. Gurbel P.A., Callahan K.P., Buczkowski M.T., et al. Does stent design affect platelet activation? Results of the platelet activation in stenting (PAST) study. [abstract] J Am Coll Cardiol. 39:2002;16A
8. Kastrati A., Schomig A., Elezi S., et al. Predictive factors of restenosis after coronary stent implantation. J Am Coll Cardiol. 30:1997;1428-1436
9. Bauters C., Hubert E., Prat A., et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol. 31:1998;1291-1298
10. Lau K.W., He Q., Ding Z.P., et al. Early experience with the NIR intracoronary stent. Am J Cardiol. 81:1998;927-929
11. Lau K.W., Ding Z.P., Sim L.L., et al. Clinical and angiographic outcome after angiography-guided stent placement in small coronary vessels. Am Heart J. 139:2000;830-839
12. Kastrati A., Mehilli J., Josef P., et al. Restenosis after coronary placement of various stent types. Am J Cardiol. 87:2001;34-39
13. Serruys P.W., Strauss B.H., Beatt K.J., et al. Angiographic follow-up after placement of a self-expanding coronary artery stent. N Engl J Med. 324:1991;13-17
14. Nageh T., de Belder A.J., Thomas M.R., et al. A randomized trial of endoluminal reconstruction comparing the NIR stent and the Wallstent in angioplasty of long segment coronary disease results of the RENEWAL study. Am Heart J. 141:2001;971-976
15. Roubin G.S., Cannon A.D., Agrawal S.K., et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation. 85:1992;916-927
16. Agrawal S.K., Ho S.W., Liu M.W., et al. Predictors of thrombotic complications after placement of the flexible coil stent. Am J Cardiol. 73:1994;1216-1219
17. Lansky A.J., Roubin G.S., O'Shaughnessy C.D., et al. Randomized comparison of GR-II stent and Palmaz-Schatz stent for elective treatment of coronary stenoses. Circulation. 102:2000;1364-1369
18. Yoshitomi Y., Kojima S., Yano M., et al. Does stent design affect probability of restenosis? A randomized trial comparing Multilink stents with GFX stents. Am Heart J. 142:2001;445-451
19. Thuesen L., Andersen H.R., Krusell L.R., et al. Randomized comparison of the coil-design Crossflex and the tubular NIR stent. Cathet Cardiovasc Intervent. 59:2003;8-12
20. Baim D.S., Cutlip D.E., O'Shaughnessy C.D., et al. Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol. 87:2001;152-156
21. Baim D.S., Cutlip D.E., Linnemeier M., et al. Final results of a randomized trial comparing the Multilink stent to the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol. 87:2001;157-162
22. Miketic S., Carlsson J., Tebbe U. Randomized comparison of J & J Crown stent versus NIR stent after routine coronary angioplasty. Am Heart J. 142:2001;e8
23. Kastrati A., Dirschinger J., Boekstegers P., et al. Influence of stent design on 1-year outcome after coronary stent placement a randomized comparison of 5 stent types in 1, 147 unselected patients. Cathet Cardiovasc Intervent. 50:2000;290-297
24. Lau K.W., Ding Z.P., Johan A., et al. Midterm clinical and angiographic follow-up outcome after placement of a new balloon expandable stent in native coronary arteries. Cathet Cardiovasc Intervent. 49:2000;348-351
25. Lincoff A.M., Furst J.G., Ellis S.G., et al. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol. 29:1997;808-816
26. Hirshfeld J.W., Schwartz J.S., Jugo R., et al. Restenosis after coronary angioplasty a multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol. 18:1991;647-656
27. Foley D.P., Melkert R., Serruys P.W. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty. Circulation. 90:1994;1239-1251
28. Mintz G.S., Popma J.J., Pichard A.D., et al. Intravascular predictors of restenosis after percutaneous transcatheter coronary revascularization. Am J Cardiol. 27:1996;1678-1687
29. Elezi S., Kastrati A., Neumann F.J., et al. Vessel size and long-term outcome after coronary stent placement. Circulation. 98:1998;1875-1880
30. Akiyama T., Moussa I., Reimers B., et al. Angiographic and clinical outcome following coronary stenting of small vessels a comparison with coronary stenting of large vessels. J Am Coll Cardiol. 32:1998;1610-1618
31. Mak K.-H., Belli G., Ellis S.G., Moliterno D.J. Subacute stent thrombosis evolving issues and current concepts. J Am Coll Cardiol. 27:1996;494-503
32. Koning R., Eltchaninoff H., Commeau P., et al. Stent placement compared with balloon angioplasty for small coronary arteries. Circulation. 104:2001;1604-1608
33. Moer R., Myreng Y., Molstad P., et al. Stenting in small coronary arteries (SISCA) trial. J Am Coll Cardiol. 38:2001;1598-1603
34. Kastrati A., Schuhlen H., Schomig A. Stenting for small coronary vessels a contestable winner. [editorial] J Am Coll Cardiol. 38:2001;1604-1607
35. Kastrati A., Mehilli J., Dirschinger J., et al. Intracoronary stenting and angiographic results strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 103:2001;2816-2821
36. Briguori C., Sarais C., Pagnotta P., et al. Instent restenosis in small coronary arteries impact of strut thickness. J Am Coll Cardiol. 40:2002;403-409
37. Taylor A. Metals. Sigwart U. Endoluminal stenting. 1996;28-33 Martin Dunitz, London (UK)
38. Tarnok A., Mahnke A., Muller M., et al. Rapid in vitro biocompatibility assay of endovascular stents by flow cytometry using platelet activation and platelet-leucocyte aggregation. Cytometry. 38:1999;30-39
39. Koster R., Vieluf D., Kiehn M., et al. Nickel and molybdenum contact allergies in patients with coronary instent restenosis. Lancet. 356:2000;1895-1897
40. Kereiakes D.J., Cox D.A., Hermiller J., et al. First use of a novel cobalt-chromium coronary stent in humans clinical and angiographic outcomes. [abstract] J Am Coll Cardiol. 41:2003;57A
41. Zidar J., Lincoff A.M., Stack R. Biodegradable stents. Topol E.J. Textbook of interventional cardiology. 2nd ed. 1994;787-802 WB Saunders, Philadelphia
42. Van der Giessen W.J., Lincoff A.M., Schwartz R.S., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary artery. Circulation. 94:1996;1690-1697
43. Chen C., Lumsden A.B., Ofenloch J.C., et al. Phosphorylcholine coating of ePTFE grafts reduces neointimal hyperplasia in canine model. Ann Vasc Surg. 11:1997;74-79
44. Tamai H., Igaki K., Kyo E., et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 102:2000;399-404
45. Tsuji T., Tamai H., Igaki K., et al. One year follow-up of biodegradable self-expanding stent implantation in humans. [abstract] J Am Coll Cardiol. 37:2001;47A
46. Briguori C., Nishida T., Anzuini A., et al. Emergency polytetrafluoroethylene-covered stent implantation to treat coronary ruptures. Circulation. 102:2000;3028-3031
47. Stefanadis C., Toutouzas K., Tsiamis E., et al. Stents covered by autologous venous grafts feasibility and immediate and long-term results. Am Heart J. 139:2000;437-445
48. Stankovic G., Colombo A., Presbitero P., et al. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts the Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) trail. Circulation. 108:2003;37-42
49. Schachinger V., Hamm C.W., Munzel T., et al. A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol. 42:2003;1360-1369
50. Hehrlein C., Zimmermann M., Metz J., et al. Influence of surface texture and charge on the biocompatibility of endovascular stents. Coron Artery Dis. 6:1995;581-586
51. Edelman E.R., Seifert P., Groothuis A., et al. Gold-coated NIR stents in porcine coronary arteries. Circulation. 103:2001;429-434
52. Zitter H., Plenk H. The electrochemical behaviour of metallic implant materials as an indicator of their biocompatibility. J Biomed Mater Res. 21:1987;881-896
53. Tanigawa N., Sawada S., Kobayashi M. Reaction of the aortic wall to 6 metallic stent materials. Acta Radiol. 2:1995;379-384
54. Alt E., Schomig A. The inflow coronary stent. Serruys P.W., Kutryk M.J.B. Handbook of coronary stents. 1998;265-273 Martin Dunitz, London, U.K.
55. Kastrati A., Schomig A., Dirschinger J., et al. Increased risk of restenosis after placement of gold-plated stents. Circulation. 101:2000;2478-2483
56. Silber S., Reifart N., Morice M.C., et al. The NUGGET trial (NIR Ultimate Gold-Gilded Equivalency Trial) 6 months post-procedure safety and efficacy results. [abstract] Circulation. 104:2001;II-623
57. Park S.J., Lee C.W., Hong M.K., et al. Comparison of gold-coated NIR stents with uncoated NIR stents in patients with coronary artery disease. Am J Cardiol. 89:2002;872-875
58. Silber S. Final results of the NIRTOP trial. Paper presented at: EuroPCR Symposium; 2003; Paris, France
59. Monnik S., van Boven A., Paals H., et al. Silicon carbide coated coronary stents have low platelet and leucocyte adhesion during platelet activation. J Invest Med. 47:1999;304-310
60. Unverdorben M., Sippel B., Degenhardt R., et al. Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings the Tenax versus NIR stent study's long-term outcome. Am Heart J. 145:2003;e17
61. Tanajura L.F., Abizaid A.A., Feres F., et al. Randomized intravascular ultrasound comparison between patients that underwent amorphous hydrogenated silicon-carbide coated stent deployment versus uncoated stents. [abstract] J Am Coll Cardiol. 41:2003;58A
62. Whelam D.M., van der Giessen W.J., Krabbendam S.C., et al. Biocompatibility of phosphorylcholine-coated stents in normal porcine coronary arteries. Heart. 83:2000;338-345
63. Moses J.W., Buller C.E.H., Nukta E.D., et al. The first clinical trial comparing a coated versus a noncoated coronary stent the Biocompatibles BiodivYsio stent in randomized control trial (DISTINCT). [abstract] Circulation. 101:2000;II-664
64. Schatz R.A., Baim D.S., Leon M.B., et al. Clinical experience with the Palmaz-Schatz coronary stent initial results of a multicenter study. Circulation. 83:1991;148-161
65. Colombo A., Hall P., Nakamura S., et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 91:1995;1676-1688
66. De S.I., Wang K., Wilczek K., et al. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stent. Circulation. 95:1997;1549-1553
67. Blezer R., Cahalan L., Cahalan P.T., et al. Heparin coating of tantalum coronary stents reduces surface thrombin generation but not factor IX a generation. Blood Coagul Fibrinolysis. 9:1998;435-440
68. Serruys P.W., van Hout B., Bonnier H., et al. Randomized comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 352:1998;673-681
69. Stone G.W., Brodie B.R., Griffin J.J., et al. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction the Primary Angioplasty in Myocardial Infarction (PAMI) Stent pilot trial. Circulation. 99:1999;1548-1554
70. Mehran R., Aymong E.D., Ashby D.T., et al. Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) Study. Circulation. 108:2003;1078-1083
71. Wohrle J., Al-Khayer U., Grotzinger C., et al. Comparison of the heparin-coated versus the uncoated Jostent - no influence on restenosis or clinical outcome. Eur Heart J. 22:2001;1808-1816
72. Haude M, Konorza TFM, Kalnins U, et al. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. Circulation 2003;107:1265-70
73. Marx S.O., Jayaram T., Go L.O., et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 76:1995;412-417
74. Morris R., Cao W., Huang X., et al. Rapamycin (sirolimus) inhibits vascular smooth muscle cell DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries evidence that rapamycin antagonizes growth factor action in immune and nonimmune cells. Transplant Proc. 27:1995;430-431
75. Gallo R., Padurean A., Chesebro J.H., et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 99:1999;2164-2170
76. Kornowski R., Hong M.K., Ragheb A.O., et al. Slow-release taxol coated GR-II stents reduce neointimal formation in porcine coronary instent restenosis model. [abstract] Circulation. 96:1997;I-341
77. Marx S.O., Andrew R.M. The development of rapamycin and its application to stent restenosis. [editorial] Circulation. 104:2001;852-855
78. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 346:2002;1773-1780
79. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 349:2003;1315-1323
80. Schofer J., Schlüter M., Gershlick A.H., et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries double-blind, randomised controlled trial (E-SIRIUS). Lancet. 362:2003;1093-1099
81. Schampaert E. Results from the Canadian multicenter, randomized, double-blind study of the sirolimus-eluting stent in the treatment of patients with de novo coronary artery lesions: C-Sirius. Paper presented at: 53rd Annual Scientific Session of the American College of Cardiology; 2003; Chicago, Ill
82. Grube E., Silber S.M., Hauptmann K.E., et al. TAXUS I 6- and 12-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 107:2003;38-42
83. Colombo A., Drzewiecki J., Banning A., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 108:2003;788-794
84. Stone GW. TAXUS IV: the pivotal, perspective, randomized trial of the slow-rate release polymer-based paclitaxel-eluting TAXUS Stent. Paper presented at: Transcatheter Therapeutics; 2003; Washington, DC
85. Gershlick AH, Descheerder I, Chevalier B, et al. Local drug delivery to inhibit coronary artery restenosis: data from the ELUTES trial [abstract]. Circulation 2001;104:II-416
86. Park S.J., Shim W.H., Ho D.S., et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 348:2003;1537-1545
87. O'Neill WW. The DELIVER Trial: a randomized comparison of paclitaxel-coated versus metallic stents for treatment of coronary lesions. Paper presented at: Annual Scientific Session of the American College of Cardiology; 2003; Chicago, Ill
88. Grube E. DELIVER II: Preliminary safety results. Paper presented at: Transcatheter Therapeutics; 2002; Washington, DC
89. Weisz G., Moses J.W., Popma J.J., et al. Do overlapping multiple Sirolimus-eluting stents impact angiographic and clinical outcomes? Insights from the SIRIUS trial. [abstract] J Am Coll Cardiol. 41:2003;33A
90. Farb A., Heller P.F., Shroff S., et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 104:2001;473-479
91. Hwang C.-W., Wu D., Edelman E.R. Physiological transport forces govern drug distribution for stent-based delivery. Circulation. 104:2001;600-605
92. Finkelstein A., McClean D., Kar S., et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation. 107:2003;777-784